SGLT2 Inhibitors for Diabetes: No Link to Fractures in Older Adults SGLT2 Inhibitors for Diabetes: No Link to Fractures in Older Adults
Analysis of Medicare data supports findings from younger adults that use of the drug class does not appear to raise fracture risk.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 27, 2021 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news
Optimal Use of SGLT2 Inhibitors and GLP-1 Agonists Optimal Use of SGLT2 Inhibitors and GLP-1 Agonists
In light of the vast benefits demonstrated by SGLT2 inhibitors and GLP-1 agonists, Dr Matthew Budoff highlights how cardiologists and preventive care physicians can optimize their use in patient care.American College of Cardiology & Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 18, 2021 Category: Consumer Health News Tags: Cardiology Article Source Type: news
Differential Mechanisms in HFrEF and HFpEF in Diabetes Differential Mechanisms in HFrEF and HFpEF in Diabetes
This review explores the pathophysiological mechanisms of heart failure in patients with diabetes, how they differ in patients with HFrEF vs. HFpEF, and the use of SGLT2 inhibitors in these patients.JACC: Heart Failure (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 8, 2021 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
Which New Drug Class Is Best for Heart Protection in Type 2 Diabetes? Which New Drug Class Is Best for Heart Protection in Type 2 Diabetes?
SGLT2 inhibitors and GLP-1 agonists appear to be equally effective at protecting against stroke and myocardial infarction in patients with type 2 diabetes, but SGLT2 inhibitors are better for heart failure.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 28, 2021 Category: Neurology Tags: Diabetes & Endocrinology News Source Type: news
Dapagliflozin Improves Physical Limitation in HFpEF: PRESERVED-HF Dapagliflozin Improves Physical Limitation in HFpEF: PRESERVED-HF
The SGLT2 inhibitor scored a clear win, showing a significant and clinically meaningful benefit after 12 weeks for the primary endpoint, a measure of symptoms and physical limitations.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 14, 2021 Category: Cardiology Tags: Cardiology News Source Type: news
SGLT2 Inhibitor Use Rising in Diabetic Kidney Disease SGLT2 Inhibitor Use Rising in Diabetic Kidney Disease
' SGLT2 inhibitors are here to stay as a new standard of care for patients with diabetic kidney disease, ' said Dr Katherine Tuttle, a nephrologist at Providence Healthcare in Spokane, Washington.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - August 24, 2021 Category: Internal Medicine Tags: Diabetes & Endocrinology News Source Type: news
Aug 13 2021 This Week in Cardiology Aug 13 2021 This Week in Cardiology
COVID-19, vaccine-induced myocarditis, Watchman complications, SGLT2 inhibitors, and cardiogenic shock are the topics John Mandrola, MD, discusses in this week ’s podcast.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 14, 2021 Category: Cardiology Tags: Cardiology Commentary Source Type: news
Dapagliflozin Safe, Protective in Advanced Kidney Disease Dapagliflozin Safe, Protective in Advanced Kidney Disease
' For clinicians, this is now the absolute reassurance that we do not have to stop an SGLT2 inhibitor ' in patients with advanced kidney disease, said Dr Chantal Mathieu, about the DAPA-CKD trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 23, 2021 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
EMPEROR-Preserved: Positive Top-Line Results for Empagliflozin in HFpEF EMPEROR-Preserved: Positive Top-Line Results for Empagliflozin in HFpEF
The SGLT2 inhibitor met the primary endpoint in adults with heart failure and preserved ejection fraction, with full results to be presented at ESC 2021.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 6, 2021 Category: Consumer Health News Tags: Cardiology News Source Type: news
Antidiabetic drug causes double the weight loss of competitor in Type 2 diabetes patients
(University at Buffalo) Patients with Type 2 diabetes who were prescribed SGLT2 inhibitors lost more weight than patients who received GLP-1 receptor agonists, according to a University at Buffalo-led study. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 1, 2021 Category: International Medicine & Public Health Source Type: news
Assays May Guide SGLT2 Inhibitor Use in High CV-Risk Diabetes Assays May Guide SGLT2 Inhibitor Use in High CV-Risk Diabetes
Not all with diabetes at heightened cardiovascular risk may benefit from some of these drugs, so how to choose? And through what mechanisms do SGLT2 inhibitors cut CV risk, anyway?Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 30, 2021 Category: Cardiology Tags: Cardiology News Source Type: news
SGLT2 Inhibitor Better Second-Line Diabetes Pick Than Sulfonylurea When Cost Is Not an Issue SGLT2 Inhibitor Better Second-Line Diabetes Pick Than Sulfonylurea When Cost Is Not an Issue
When metformin fails to sufficiently lower blood glucose levels, it ' s better to add an SGLT2 inhibitor rather than a sulfonylurea, according to a comparative effectiveness analysis.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 30, 2021 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
MRAs and SGLT2 Inhibitors: The Best of Both Worlds in HFrEF MRAs and SGLT2 Inhibitors: The Best of Both Worlds in HFrEF
What benefits might the use of these treatments together offer in the management of heart failure with reduced ejection fraction?JACC: Heart Failure (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 22, 2021 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
Dapagliflozin Misses in COVID-19 but Intriguing Signal of Benefit Dapagliflozin Misses in COVID-19 but Intriguing Signal of Benefit
The SGLT2 inhibitor dapagliflozin was not associated with significant benefit in COVID-19 patients but came close in the DARE-19 trial.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 18, 2021 Category: Cardiology Tags: Cardiology News Source Type: news
Dapagliflozin did not significantly reduce organ failure or death in high-risk patients hospitalized
(American College of Cardiology) Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, did not significantly reduce the risk of organ failure or death or improve recovery in patients hospitalized with COVID-19 who are at high risk of developing serious complications compared to placebo, according to data presented at the American College of Cardiology's 70th Annual Scientific Session. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - May 16, 2021 Category: Infectious Diseases Source Type: news
